196 related articles for article (PubMed ID: 37469152)
1. Proteasome as a Drug Target in Trypanosomatid Diseases.
Silva ML; de Santiago-Silva KM; Fabris M; Camargo PG; de Lima Ferreira Bispo M
Curr Drug Targets; 2023; 24(10):781-789. PubMed ID: 37469152
[TBL] [Abstract][Full Text] [Related]
2. Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness.
Khare S; Nagle AS; Biggart A; Lai YH; Liang F; Davis LC; Barnes SW; Mathison CJ; Myburgh E; Gao MY; Gillespie JR; Liu X; Tan JL; Stinson M; Rivera IC; Ballard J; Yeh V; Groessl T; Federe G; Koh HX; Venable JD; Bursulaya B; Shapiro M; Mishra PK; Spraggon G; Brock A; Mottram JC; Buckner FS; Rao SP; Wen BG; Walker JR; Tuntland T; Molteni V; Glynne RJ; Supek F
Nature; 2016 Sep; 537(7619):229-233. PubMed ID: 27501246
[TBL] [Abstract][Full Text] [Related]
3. Drug discovery for the treatment of leishmaniasis, African sleeping sickness and Chagas disease.
Future Med Chem; 2013 Oct; 5(15):1709-18. PubMed ID: 24144408
[TBL] [Abstract][Full Text] [Related]
4. Metallodrugs for the Treatment of Trypanosomatid Diseases: Recent Advances and New Insights.
Navarro M; Justo RMS; Delgado GYS; Visbal G
Curr Pharm Des; 2021; 27(15):1763-1789. PubMed ID: 33185155
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological approaches to antitrypanosomal chemotherapy.
Croft SL
Mem Inst Oswaldo Cruz; 1999; 94(2):215-20. PubMed ID: 10224531
[TBL] [Abstract][Full Text] [Related]
6. Small molecules containing chalcogen elements (S, Se, Te) as new warhead to fight neglected tropical diseases.
Henriquez-Figuereo A; Morán-Serradilla C; Angulo-Elizari E; Sanmartín C; Plano D
Eur J Med Chem; 2023 Jan; 246():115002. PubMed ID: 36493616
[TBL] [Abstract][Full Text] [Related]
7. Microbial proteasomes as drug targets.
Zhang H; Lin G
PLoS Pathog; 2021 Dec; 17(12):e1010058. PubMed ID: 34882737
[TBL] [Abstract][Full Text] [Related]
8. Trypanosomatid parasites causing neglected diseases.
Nussbaum K; Honek J; Cadmus CM; Efferth T
Curr Med Chem; 2010; 17(15):1594-617. PubMed ID: 20166934
[TBL] [Abstract][Full Text] [Related]
9. Aminoacyl-tRNA synthetase (AARS) as an attractive drug target in neglected tropical trypanosomatid diseases-Leishmaniasis, Human African Trypanosomiasis and Chagas disease.
Kushwaha V; Capalash N
Mol Biochem Parasitol; 2022 Sep; 251():111510. PubMed ID: 35988745
[TBL] [Abstract][Full Text] [Related]
10. Further Investigations of Nitroheterocyclic Compounds as Potential Antikinetoplastid Drug Candidates.
García-Estrada C; Pérez-Pertejo Y; Domínguez-Asenjo B; Holanda VN; Murugesan S; Martínez-Valladares M; Balaña-Fouce R; Reguera RM
Biomolecules; 2023 Apr; 13(4):. PubMed ID: 37189384
[TBL] [Abstract][Full Text] [Related]
11. Anti-trypanosomatid drug discovery: progress and challenges.
De Rycker M; Wyllie S; Horn D; Read KD; Gilbert IH
Nat Rev Microbiol; 2023 Jan; 21(1):35-50. PubMed ID: 35995950
[TBL] [Abstract][Full Text] [Related]
12. Parasite prolyl oligopeptidases and the challenge of designing chemotherapeuticals for Chagas disease, leishmaniasis and African trypanosomiasis.
Bastos IM; Motta FN; Grellier P; Santana JM
Curr Med Chem; 2013; 20(25):3103-15. PubMed ID: 23514419
[TBL] [Abstract][Full Text] [Related]
13. Targeting cysteine proteases in trypanosomatid disease drug discovery.
Ferreira LG; Andricopulo AD
Pharmacol Ther; 2017 Dec; 180():49-61. PubMed ID: 28579388
[TBL] [Abstract][Full Text] [Related]
14. The kinetoplastid chemotherapy revisited: current drugs, recent advances and future perspectives.
Castillo E; Dea-Ayuela MA; Bolás-Fernández F; Rangel M; González-Rosende ME
Curr Med Chem; 2010; 17(33):4027-51. PubMed ID: 20939823
[TBL] [Abstract][Full Text] [Related]
15. High-throughput screening platform for natural product-based drug discovery against 3 neglected tropical diseases: human African trypanosomiasis, leishmaniasis, and Chagas disease.
Annang F; Pérez-Moreno G; García-Hernández R; Cordon-Obras C; Martín J; Tormo JR; Rodríguez L; de Pedro N; Gómez-Pérez V; Valente M; Reyes F; Genilloud O; Vicente F; Castanys S; Ruiz-Pérez LM; Navarro M; Gamarro F; González-Pacanowska D
J Biomol Screen; 2015 Jan; 20(1):82-91. PubMed ID: 25332350
[TBL] [Abstract][Full Text] [Related]
16. Novel compounds to combat trypanosomatid infections: a medicinal chemical perspective.
González M; Cerecetto H
Expert Opin Ther Pat; 2011 May; 21(5):699-715. PubMed ID: 21428846
[TBL] [Abstract][Full Text] [Related]
17. Management of trypanosomiasis and leishmaniasis.
Barrett MP; Croft SL
Br Med Bull; 2012; 104(1):175-96. PubMed ID: 23137768
[TBL] [Abstract][Full Text] [Related]
18. Targeting the polyamine biosynthetic enzymes: a promising approach to therapy of African sleeping sickness, Chagas' disease, and leishmaniasis.
Heby O; Persson L; Rentala M
Amino Acids; 2007 Aug; 33(2):359-66. PubMed ID: 17610127
[TBL] [Abstract][Full Text] [Related]
19. Research priorities for Chagas disease, human African trypanosomiasis and leishmaniasis.
World Health Organization
World Health Organ Tech Rep Ser; 2012; (975):v-xii, 1-100. PubMed ID: 23484340
[TBL] [Abstract][Full Text] [Related]
20. The Amazing World of Peptide Engineering: the Example of Antimicrobial Peptides from Frogs and Their Analogues.
Guimarães AB; Costa FJ; Pires OR; Fontes W; Castro MS
Protein Pept Lett; 2016; 23(8):722-37. PubMed ID: 27262306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
